EUCTR2007-006934-33-BE进行中(未招募)1 期
A single center, open-label trial in subjects with severe renal impairment evaluating the dialysability of the sugammadex-rocuronium complex
V Organon0 个研究点目标入组 15 人开始时间: 2008年1月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At least 18 years of age
- •ASA Class = 4
- •Creatinine clearance (CLCR) < 30 mL/min and clinical indication for dialysis
- •Hospitalization at ICU and scheduled for a (surgical) procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium
- •Scheduled for a (surgical) procedure in supine position
- •Written informed consent (of the legal representative)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant hepatic dysfunction
- •Subjects known or suspected to have a (family) history of malignant hyperthermia
- •Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia
- •Subjects who have already participated in a sugammadex trial
- •Subjects who have participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into 19.4.333
- •Female subjects who are pregnant*
- •Female subjects who are breast-feeding
- •* In female subjects pregnancy will be excluded both from medical history and by an hCG test within 24 hours before surgery except in females who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or an hysterectomy.
研究者
相似试验
已完成
不适用
A single centre, open label trial investigating the absorption, metabolism and excretion of somapacitan after single subcutaneous dosing in healthy male subjectsgroeihormoondeficientiegrowth hormone deficiencyNL-OMON42854ovo Nordisk A/S7
进行中(未招募)
1 期
Investigation of acceptance, usability, safety and efficacy of the GlucoTab@MobileCare system for type 2 diabetes in domiciliary nursing careDiabetes mellitus type 2MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-000863-98-ATMedical University of Graz10
已完成
4 期
A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for glycaemic management in patients with type 2 diabetes receiving domiciliary nursing careE11Type 2 diabetes mellitusDRKS00015059Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Diabetologie9
进行中(未招募)
不适用
An open single center study investigating the effects and side-effects of CRD007 in children with Duchenne Muscular Dystrophy (DMD -an inherited disorder which results in muscle degeneration) or Becker Muscular Dystrophy (BMD- an inherited disorder characterized by slowly progressive muscle weakness of the legs and pelvis) or children being symptomatic carriers for DMD or BMD.EUCTR2011-004667-76-SECardoz AB
已完成
1 期
A single dose study in healthy Japanese participants to evaluate the safety and pharmacokinetics of otilimab.Rheumatoid ArthritisJPRN-jRCT2071210132Yamada Masanori12
